MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

grant a product specific waiver

MHRA-100995-PIP01-23

Scope of the Application

Active Substance(s)

LysoPhosphatidic Acid receptor 1 (LPA1) antagonist (BMS-986278)

Condition(s)

Treatment of fibrosing Interstitial Lung Diseases (ILD)

Pharmaceutical Form(s)

All pharmaceutical forms

Route(s) of Administration

All routes of administration

Name / Corporate name of the PIP applicant

Bristol-Myers Squibb Pharma EEIG

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Bristol-Myers Squibb Pharma EEIG submitted to the licensing authority on 05/05/2023 15:05 BST an application for a Waiver

The procedure started on 26/09/2023 09:21 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to grant a product specific waiver

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100995-PIP01-23

Of 13/10/2023 11:35 BST

On the adopted decision for LysoPhosphatidic Acid receptor 1 (LPA1) antagonist (BMS-986278) (MHRA-100995-PIP01-23) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Granting a waiver in all age groups for the listed condition(s)

This decision applies to a Waiver for LysoPhosphatidic Acid receptor 1 (LPA1) antagonist (BMS-986278), All pharmaceutical forms , All routes of administration .

This decision is addressed to Bristol-Myers Squibb Pharma EEIG, Plaza 254, Blanchardstown Corporate Park 2, Ballycoolin, Dublin 15, IRELAND, D15 T867

ANNEX I

1. Waiver

1.1 Condition:

Treatment of fibrosing Interstitial Lung Diseases (ILD) The waiver applies / applied to: Paediatric Subset(s): All subsets of the paediatric population from birth to less than 18 years of age Pharmaceutical form(s): All pharmaceutical forms Route(s) of administration: All routes of administration Reason for granting waiver: on the grounds that the specific medicinal product is likely to be unsafe.

2. Paediatric Investigation Plan:

2.1 Condition(s):

Not applicable

2.2 Indication(s) targeted by the PIP:

Not applicable

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

Not applicable

2.4 Pharmaceutical Form(s):

Not applicable

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures		
Non-Clinical Studies		
Clinical Studies		
Extrapolation, Modeling & Simulation Studies		
Other Studies		
Other Measures		

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	
Date of completion of the paediatric investigation plan:	
Deferral of one or more studies contained in the paediatric investigation plan:	